Publications by authors named "M Keltai"
Background: Many patients with atrial fibrillation suffer from comorbid vascular disease. The comparative efficacy and safety of different types of oral anticoagulation (OAC) in this patient group have not been widely studied.
Methods: Adults with newly diagnosed atrial fibrillation were recruited into the prospective observational registry, GARFIELD-AF, and followed for 24 months.
Article Synopsis
- This study investigates how diabetes mellitus (DM) affects the management and outcomes of patients with newly diagnosed atrial fibrillation (AF) and evaluates the impact of oral anticoagulation (OAC) on these patients.
- The research analyzed data from over 52,000 patients in the GARFIELD-AF registry, comparing those with DM and those without, while focusing on how OAC use influenced their mortality and stroke risks.
- Findings showed that both DM and non-DM patients experienced lower risks of death and stroke with OAC, while patients with insulin-requiring DM saw significant benefits from OAC usage, despite an increased risk of major bleeding.*
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
Eur Heart J Cardiovasc Pharmacother
December 2022
Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial who were treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily during long-term open-label extension (LTOLE).
Methods And Results: Of the 27 395 patients enrolled in COMPASS, 12 964 (mean age at baseline 67.
Background: Among patients with diabetes and chronic coronary disease, it is unclear if invasive management improves outcomes when added to medical therapy.
Methods: The ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trials (ie, ISCHEMIA and ISCHEMIA-Chronic Kidney Disease) randomized chronic coronary disease patients to an invasive (medical therapy + angiography and revascularization if feasible) or a conservative approach (medical therapy alone with revascularization if medical therapy failed). Cohorts were combined after no trial-specific effects were observed.
Aims: The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial prespecified an analysis to determine whether accounting for recurrent cardiovascular events in addition to first events modified understanding of the treatment effects.
Methods And Results: Patients with stable coronary artery disease (CAD) and moderate or severe ischaemia on stress testing were randomized to either initial invasive (INV) or initial conservative (CON) management. The primary outcome was a composite of cardiovascular death, myocardial infarction (MI), and hospitalization for unstable angina, heart failure, or cardiac arrest.